Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, entered a manufacturing partnership to advance Ray Therapeutics’ lead optogenetics gene therapy program, Ray-001, into clinical trials for patients with retinitis pigmentosa.
 

Forge will provide adeno-associated viral (AAV) process development, scale-up engineering and cGMP manufacturing services for Ray’s program, Ray-001. The program will use Forge’s platform process including its proprietary HEK 293 suspension Ingition Cells and pEMBR adenovirus helper plasmid. All development and cGMP manufacturing activities will occur at The Hearth, Forge’s 200,000 ft2 gene therapy cGMP production facility in Columbus, OH.
 

“We have set up Forge to provide end-to-end gene therapy manufacturing services to enable support for clients striving to make significant improvements in patients’ lives,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge. “We look forward to helping Ray Therapeutics advance their AAV manufacturing with an eye towards restoring vision in patients with ophthalmology disorders.”
 

“Ray-001 is a ground-breaking new approach to treat inherited retinal diseases using the power of optogenetics, and working together with Forge, we are one step closer to restoring vision in patients who are going blind,” said Paul Bresge, CEO of Ray Therapeutics.